Expression of thymidylate synthase and dihydropyrimidine dehydrogenase in oral squamous cell carcinoma: Possible markers as predictors of clinical outcome

Acta Oto-Laryngologica

Volumn 126, Issue 12, 2006, Pages 1295-1302

  Sakakura, Koichi ^a   Chikamatsu, Kazuaki ^a   Shino, Masato ^a   Sakurai, Tsutomu ^a   Furuya, Nobuhiko ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Dihydropyrimidine dehydrogenase; Oral squamous cell carcinoma; P glycoprotein; p53; Thymidylate synthase

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; GLYCOPROTEIN P; MESSENGER RNA; PROTEIN; PROTEIN P53; PROTEIN TS; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER RELAPSE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MOUTH CARCINOMA; PATHOLOGY; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; P-GLYCOPROTEIN; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THYMIDYLATE SYNTHASE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33751091249     PISSN: 00016489     EISSN: 16512553     Source Type: Journal    
DOI: 10.1080/00016480600606624     Document Type: Article

References (26)

1. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330-8.
2. Banwejee D, Mayer-Kuckuk P, Capiaux G, Budak-Alpdogan T, Gorlick R, Bertino JR. Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochim Biophys Acta 2002;1587:164-73.
3. Omura K. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines. Int J Clin Oncol 2003;8:132-8.
4. Allegra CJ, Paik S, Colangelo LH, Parr AL, Kirsch I, Kim G, et al. Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol 2003;21: 241-50.
5. Kawasaki G, Yoshitomi I, Yanamoto S, Mizuno A. Thymidylate synthase and dihydropyrimidine dehydrogenase expression in oral squamous cell carcinoma: an immunohistochemical and clinicopathologic study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002;94:717-23.
6. Kornmann M, Schwabe W, Sander S, Kron M, Strater J, Polat S, et al. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin Cancer Res 2003;9:4116-24.
7. Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N, Drake JC, et al. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994;12: 2640-7.
8. Johnston PG, Mick R, Recant W, Behan KA, Dolan ME, Ratain MJ, et al. Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. J Natl Cancer Inst 1997; 89:308-13.
9. Shiga H, Heath EI, Rasmussen A, Trock B, Johnston PG, Forastiere AA, et al. Prognostic value of p53, glutathione S-transferase π, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. Clin Cancer Res 1999;5:4097-104.
10. Kobayashi H, Koike T, Nakatsuka A, Kurita H, Sagara J, Taniguchi S, et al. Dihydropyrimidine dehydrogenase expression predicts survival outcome and chemosensitivity to 5-fluorouracil in patients with oral squamous cell carcinoma. Oral Oncol 2005;41:38-47.
11. Obata A, Eura M, Sasaki J, Saya H, Chikamatsu K, Tada M, et al. Clinical significance of p53 functional loss in squamous cell carcinoma of the oropharynx. Int J Cancer 2000;89: 187-93.
12. Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, et al. Internal duplication and homology with bacterial transport proteins in the MDR1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986;47:381-9.
13. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258:1650-4.
14. Kato A, Miyazaki M, Ambiru S, Yoshiotmi H, Ito H, Nakagawa K, et al. Multidrug resistance gene (MDR-1) expression as a useful prognostic factor in patients with human hepatocellular carcinoma after surgical resection. J Surg Oncol 2001;78:110-5.
15. Raspadori D, Damiani D, Michieli M, Stocchi R, Gentili S, Gozzetti A, et al. CD56 and PGP expression in acute myeloid leukemia: impact on clinical outcome. Haematologica 2002;87:1135-40.
16. Sakakura K, Chikamatsu K, Sakurai T, Takahashi K, Murata T, Oriuchi N, et al. Infiltration of dendritic cells and NK cells into the sentinel lymph node in oral cavity cancer. Oral Oncol 2005;41:89-96.
17. Ichikawa W, Takahashi T, Suto K, Nihei Z, Shirota Y, Shimizu M, et al. Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in relation to differentiation of gastric cancer. Int J Cancer 2004;112:967-73.
18. Uematsu T, Hasegawa T, Hiraoka BY, Komatsu F, Matsuura T, Yamada A, et al. Multidrug resistance gene 1 expression in salivary gland adenocarcinomas and oral squamous-cell carcinomas. Int J Cancer 2001;92:187-94.
19. Danenberg PV. Thymidylate synthase - a target enzyme in cancer chemotherapy. Biochem Biophys Acta 1977;473: 73-92.
20. Lizard-Nacol S, Genne P, Coudert B, Riedinger JM, Arnal M, Sancy C, et al. MDR1 and thymidylate synthase (TS) gene expressions in advanced breast cancer: relationships to drug exposure, p53 mutations, and clinical outcome of the patients. Anticancer Res 1999;19:3575-81.
21. Miyoshi T, Kondo K, Fujino H, Takahashi Y, Sawada N, Sakiyama S, et al. Thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer: relationship between mRNA expression and activity. Anticancer Res 2005;25:923-30.
22. Fujiwaki R, Iida K, Nakayama K, Kanasaki H, Ozaki T, Hata K, et al. Dihydropyrimidine dehydrogenase in normal and malignant endometrium: relationship with cell proliferation and thymidine phosphorylase. Virchows Arch 2003;443: 672-7.
23. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996;88:1442-55.
24. Etienne MC, Chazal M, Laurent-Puig P, Magne M, Rosty C, Formento JL, et al. Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. J Clin Oncol 2002;20:2832-43.
25. Jain V, Das SN, Luthra K, Shukla NK, Ralhan R. Differential expression of multidrug resistance gene product, P-glycoprotein, in normal, dysplastic and malignant oral mucosa in India. Int J Cancer 1997;74:128-33.
26. Cho YS, Kim MJ. Expression of multidrug resistance-related genes in oral squamous cell carcinomas. Oral Oncol 2001;37:652-9.